News

Lecanemab binds with high affinity to soluble amyloid-beta protofibrils. It won full FDA approval in July 2023 based on trial ...
Significant adverse events — such as ARIA — with lecanemab, the drug that slows Alzheimer's, is rare and manageable, ...
Women are more likely to get Alzheimer's, and the way the disease works in their body may provide key insights about how it ...
The findings show that memory clinics can have “the infrastructure and expertise to safely administer and care for patients ...